Conclusion
emesis, nausea and vomiting, CINV
A single dose of NEPA, administered on day 1 only, was more effective than a 3‐day aprepitant regimen in preventing CINV for an extended duration in patients receiving MEC and in those with emetic risk factors.This was a post‐hoc analysis of a pragmatic prospective study exploring the comparative efficacy of NEPA versus an aprepitant regimen in preventing chemotherapy‐induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy and in a subset of those with emetic risk factors. This study uniquely assessed complete response (CR: no emesis and no rescue use) rates up to 144 h post‐chemotherapy. Significantly higher CR rates were seen for NEPA than aprepitant during the extended overall phase for all patients receiving MEC (NEPA 77.1%, aprepitant 57.8%, 
